Navigation Links
Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins

LONDON, March 26, 2012 /PRNewswire/ --

Results presented from new VOYAGER sub-analysis


AstraZeneca today announced the results of a sub-analysis from the VOYAGER individual patient data meta-analysis, which suggests that achieving an LDL-C goal of <70 mg/dL or >50% reduction in LDL-C levels in patients at high risk requires aggressive statin therapy. These goals reflect the latest European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Guidelines for the Management of Dyslipidaemias. Results showed that a significantly greater percentage of patients achieved this goal with CRESTOR™ (rosuvastatin) than with equal or double doses of atorvastatin (Lipitor®) or simvastatin. These findings were presented at the 2012 International Symposium on Atherosclerosis in Sydney, Australia.

This sub-analysis was designed to determine the percentage of high-risk patients treated with rosuvastatin 10-40 mg, atorvastatin 10-80 mg or simvastatin 10-80 mg who achieved this recommended LDL-C goal. Additional findings from the VOYAGER sub-analysis included:

  • As statin dose increased, a higher percentage of patients achieved LDL-C <70 mg/dL or >50% LDL-C reduction.
  • Statistically significant differences (all p<0.001)were observed across a range of statin therapy comparisons, including:
  • Rosuvastatin 10mg vs atorvastatin 10-20mg and simvastatin 10-20mg
  • Rosuvastatin 20mg vs atorvastatin 20-40mg and simvastatin 20-80mg
  • Rosuvastatin 40mg vs atorvastatin 40-80mg and simvastatin 40-80mg

Percentage of high-risk patients achieving LDL-C goal


     (Photo: )


"These data reinforce CRESTOR as an important medication that helps get high-risk patients to recommended treatment targets" said Russ Esterline, VP Global Product Development Cardiovascular, AstraZeneca. "Additionally, these favourable results add to the wealth of data that demonstrate CRESTOR is well positioned in the market to remain a statin of choice for physicians treating patients at increased-risk."

Guidelines continue to stress the importance of achieving aggressive LDL-C treatment goals in higher risk patients and the important role of statins in achieving these goals. Under the recently updated ESC/EAS guidelines, target LDL-C goals have become more stringent, particularly for patients with established cardiovascular disease, type II diabetes and for other patients classified as being at very high risk of a primary or secondary cardiovascular event.The ESC/EAS guidelines recommend that clinicians should aim for LDL-C levels below <3.0 mmol/L (~115 mg/dL) in moderate risk patients, <2.5 mmol/L (~100 mg/dL) in high-risk patients and <1.8 mmol/L (~70 mg/dL) and/or at least 50 percent reduction in levels if this target cannot be reached in very high-risk patients.

CRESTOR has been researched extensively for over 13 years, including 120 clinical trials of more than 67,000 patients worldwide from more than 55 countries.


VOYAGER (An indiVidual patient data meta-analysis Of statin therapY in At risk Groups: Effects of Rosuvastatin, atorvastatin and simvastatin) is a unique individual patient data  meta-analysis of 32 258 patients from 37 randomised studies comparing the lipid modifying effects of rosuvastatin with that of atorvastatin and simvastatin. The patients include almost 9,000 with diabetes and over 15,000 with atherosclerotic disease.

CRESTOR has now received regulatory approvals in over 109 countries. Worldwide, doctors have written nearly 330 million prescriptions for CRESTOR.Data from clinical trials and real world use shows that the safety profile for rosuvastatin is in line with that of other marketed statins.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:

SOURCE AstraZeneca
Copyright©2010 PR Newswire.
All rights reserved

Related biology news :

1. Global commission delivers food security policy recommendations
2. Partnership delivers asthma care to children whose care centers were flooded by Katrina
3. Three-part handoff delivers proteins to membrane surface
4. Cell Press delivers the news
5. Global Rainmakers Delivers World Class Iris Capability for Portoss
6. DigitalPersona Delivers New Centrally-Managed Solution for Notebook Data Protection and Remote Access Security
7. Homex Delivers Solid Q-1 2010 Revenue Growth of 12.2 Percent
8. BIO-key(R) Delivers FBI-Compliant 2 Factor Authentication Solution for First Responders
9. ESAs ice mission delivers first data
10. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
11. Toxicologists annual meeting in San Francisco to showcase the latest scientific achievements
Post Your Comments:
(Date:11/12/2015)... Nov. 12, 2015  A golden retriever that stayed ... dystrophy (DMD) has provided a new lead for treating ... the Broad Institute of MIT and Harvard and the ... . Cell, pinpoints a protective ... the disease,s effects. The Boston Children,s lab of ...
(Date:11/10/2015)... , Nov. 10, 2015  In ... on the basis of product, type, application, ... included in this report are consumables, services, ... report are safety biomarkers, efficacy biomarkers, and ... this report are diagnostics development, drug discovery ...
(Date:11/4/2015)... New York , November 4, 2015 ... to a new market report published by Transparency Market ... Share, Growth, Trends and Forecast 2015 - 2022", the global ... of US$ 30.3 bn by 2022. The market is ... the forecast period from 2015 to 2022. Rising security ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... Nov. 24, 2015 /CNW/ - iCo Therapeutics ("iCo" or ... financial results for the quarter ended September 30, ... Canadian dollars and presented under International Financial Reporting ... ," said Andrew Rae , President ... iCo-008 are not only value enriching for this ...
(Date:11/24/2015)... ... 2015 , ... International Society for Pharmaceutical Engineering (ISPE) closed ... events for pharmaceutical manufacturing: 2015 Annual Meeting. The conference took place in Philadelphia, ... number of attendees in more than a decade. , “The 2015 Annual ...
(Date:11/24/2015)... N.C. , Nov. 24, 2015  Clintrax Global, Inc., a ... North Carolina , today announced that the company has set ... represented a 391% quarter on quarter growth posted for Q3 of ... and Mexico , with the establishment ... in December 2015. --> United Kingdom ...
(Date:11/24/2015)... ... ... This fall, global software solutions leader SAP and AdVenture Capital brought together ... their BIG ideas to improve health and wellness in their schools. , Now, the ... title of SAP's Teen Innovator, an all-expenses paid trip to Super Bowl 50, and ...
Breaking Biology Technology: